IGC Pharma Inc IGC

Healthcare Cannabis

IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aß plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aß plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aß plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.

NYSEAM:IGC - Post by User

IGC Pharma Inc

<< Previous

Bullboard Posts

Post by whytestockson Sep 18, 2024 6:17pm

48 Views

Post# 36229985

InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Re

News; $IGC InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1's Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer'sIGC Pharma (NYSE American: IGC) , an AI-powered, clinical-stage biotechnology company, today announced data that supports the therapeutic potential of IGC-AD1 as a disease modifying treatment for Alzheimer’s. According to the announcement, findings from studies have shown that IGC-AD1 has ...IGC - InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1's Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer's

<< Previous

Bullboard Posts

These are the world's 10 largest lithium mines